secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2026-07-14T13:20:16+00:00
Accession:  0001193125-26-302660
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand completes acquisition of XOMA Royalty for $739M; portfolio exceeds 200 assets
--------------------------------------------------------------------------------

- Total equity value ~$739M; XOMA Royalty stockholders received $39/share cash plus one CVR per share.
- Adds seven commercial products including VABYSMO, OJEMDA, and MIPLYFFA, plus 14 late-stage programs.
- Portfolio more than doubled to over 200 commercial, clinical, and preclinical royalty assets.
- Transaction expected to add ~$0.50 to 2026 and ~$1.50 to 2027 adjusted EPS; accretive immediately.
- New $125M revolving credit facility with maturity Sept 2028; covenants include min EBITDA of $100M-$150M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000119312526302660/0001193125-26-302660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000119312526302660/d108457d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-302660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer